Kimal has extended its UK and Ireland distribution agreement with its partner Tauropharm with the signing of a new long-term contract.
The deal will see the company act as the British and Irish seller of the Tauropharm catheter locking solution, which complements existing Kimal offerings such as the Altius central venous catheters and insertion procedure packs.
Taurolock combines an effective antimicrobial and anticoagulant to deliver a biocompatible solution, which can maintain catheter patency and also create an environment hostile to bacteria and fungal growth.
It is specifically designed for haemodialysis, oncology, haematology and parenteral nutrition patients with long and short-term catheters and contains no antibiotics, thus reducing the threat posed by bacterial resistance.
This latest deal cements a long-term alliance between Kimal and Tauropharm that originally began six years ago.
A statement from Kimal said: "Taurolock is a perfect strategic fit within our vascular business supporting our range of vascular catheters."See all the latest jobs in Medical Devices